159 related articles for article (PubMed ID: 20106344)
21. [Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].
Elovaara I; Atula S; Erälinna JP; Färkkilä M; Pirttilä T; Remes A; Ruutiainen J; Varis T; ;
Duodecim; 2010; 126(2):199-200. PubMed ID: 20405605
[TBL] [Abstract][Full Text] [Related]
22. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients.
Lebrun C; Bensa C; Debouverie M; Wiertlevski S; Brassat D; de Seze J; Rumbach L; Pelletier J; Labauge P; Brochet B; Tourbah A; Clavelou P;
Arch Neurol; 2009 Jul; 66(7):841-6. PubMed ID: 19597085
[TBL] [Abstract][Full Text] [Related]
23. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
[TBL] [Abstract][Full Text] [Related]
24. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.
Goodin DS; Bates D
Mult Scler; 2009 Oct; 15(10):1175-82. PubMed ID: 19737851
[TBL] [Abstract][Full Text] [Related]
25. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis.
Rovira A; Swanton J; Tintoré M; Huerga E; Barkhof F; Filippi M; Frederiksen JL; Langkilde A; Miszkiel K; Polman C; Rovaris M; Sastre-Garriga J; Miller D; Montalban X
Arch Neurol; 2009 May; 66(5):587-92. PubMed ID: 19433658
[TBL] [Abstract][Full Text] [Related]
26. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis.
Sombekke MH; Wattjes MP; Balk LJ; Nielsen JM; Vrenken H; Uitdehaag BM; Polman CH; Barkhof F
Neurology; 2013 Jan; 80(1):69-75. PubMed ID: 23243070
[TBL] [Abstract][Full Text] [Related]
27. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
Comi G
Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
[TBL] [Abstract][Full Text] [Related]
28. Disease-modifying drugs for the early treatment of multiple sclerosis.
Flachenecker P
Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
[TBL] [Abstract][Full Text] [Related]
29. [Acute posterior cord lesions in multiple sclerosis. An MRI study of the clinical course in 20 cases].
Pou Serradell A; Roquer González J; Perich Alsina X
Rev Neurol (Paris); 2000 Dec; 156(12):1126-35. PubMed ID: 11139729
[TBL] [Abstract][Full Text] [Related]
30. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
Wolinsky JS; Narayana PA; Johnson KP;
Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial.
Rovaris M; Comi G; Rocca MA; Valsasina P; Ladkani D; Pieri E; Weiss S; Shifroni G; Wolinsky JS; Filippi M;
Mult Scler; 2007 May; 13(4):502-8. PubMed ID: 17483532
[TBL] [Abstract][Full Text] [Related]
32. Defining interferon beta response status in multiple sclerosis patients.
Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
[TBL] [Abstract][Full Text] [Related]
33. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
[TBL] [Abstract][Full Text] [Related]
34. [Magnetic resonance in the diagnosis and treatment of multiple sclerosis].
Rovira Cañellas A
Neurologia; 2000; 15(7):288-302. PubMed ID: 11075577
[TBL] [Abstract][Full Text] [Related]
35. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
Thrower BW
Neurology; 2007 Jun; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
[TBL] [Abstract][Full Text] [Related]
36. [Cerebral and spinal MRI examination in patients with clinically isolated syndrome and definite multiple sclerosis].
Sailer M; Fazekas F; Gass A; Kappos L; Radue EW; Rieckmann P; Toyka K; Wiendl H; Bendszus M
Rofo; 2008 Nov; 180(11):994-1001. PubMed ID: 18937154
[TBL] [Abstract][Full Text] [Related]
37. Acute inflammatory demyelinating optic neuritis: evidence-based visual and neurological considerations.
Abou Zeid N; Bhatti MT
Neurologist; 2008 Jul; 14(4):207-23. PubMed ID: 18617847
[TBL] [Abstract][Full Text] [Related]
38. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults.
Waubant E; Chabas D; Okuda DT; Glenn O; Mowry E; Henry RG; Strober JB; Soares B; Wintermark M; Pelletier D
Arch Neurol; 2009 Aug; 66(8):967-71. PubMed ID: 19667217
[TBL] [Abstract][Full Text] [Related]
39. Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
Moreau T
J Neurol Sci; 2009 Feb; 277 Suppl 1():S12-5. PubMed ID: 19200858
[TBL] [Abstract][Full Text] [Related]
40. Impact of diagnosis and early treatment on the course of multiple sclerosis.
Noyes K; Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
